Hikma FDA dispute lines Novartis' Sandoz up for Advair coup

The FDA is locked in a dispute with Hikma over the drugmaker's copy of GlaxoSmithKline's Advair.

Those waiting for Hikma and Vectura’s copy of GlaxoSmithKline blockbuster Advair may be waiting awhile.

After receiving a May rejection of the knockoff from the FDA, Hikma now says the partners are locked in a dispute with the agency that won’t be resolved until next year’s first quarter. Once that’s settled, “we will update the market and provide further details on timelines,” the company said in a statement.

RELATED: Glaxo scores again as FDA strikes down would-be Advair copycats Hikma, Vectura


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

At the root of the tussle is “an outstanding issue” regarding the team’s clinical endpoint study, according to Hikma, which says it “firmly” disagrees with the FDA’s position. The rest of the questions regulators raised around the turned-down application have been clarified and addressed, the drugmaker added.

Hikma’s lengthy delay could make Novartis’ Sandoz a come-from-behind winner in the race to bring a cheap copy of GSK’s respiratory blockbuster to market. Before Hikma, Mylan saw its own application turned aside by the FDA, and it’s since removed the product from its 2017 guidance.

RELATED: Novartis, late to the Advair generics party, urges FDA to block rival copycats

That leaves Sandozwhich was once lagging far enough behind that it filed a citizen petition urging the FDA toward stricter approval standardspotentially first in line for a green light. And at least one analyst thinks the company might have the petition to thank.

Meanwhile, Glaxo will take all the copycat-free time it can get with Advair, whose respiratory sales have dwindled under payer pressure even in the absence of generic competition. On its earnings call late last month, the British drugmaker outlined “ongoing pressures” in the business for next year, which doesn’t seem to present “a lot to look forward to,” Bernstein analyst Tim Anderson wrote to clients at the time.

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.